MEDIA ADVISORY: BIO VentureForum 2002

8:30 - 8:50 a.m.
The Current Environment for Venture Financing
Mark Heesen, president, National Venture Capital Association
8:50 - 10:15 a.m.
Private Financing in Challenging Times: The shifting public market has created new pressures on both private company management and investors. This panel will look at challenges such as balancing changing valuation expectations and corporate governance while looking forward to the next "public window."

Moderator: George Milstein, senior managing director, Pacific Growth Equities, Inc.

Panelists: Bill Harris, MBA, senior vice president of finance, XenoPort, Inc.; Robert Blum, senior vice president, finance and corporate development and CFO, CytoKinetics, Inc.; Rod Ferguson, managing director, JP Morgan Partners; Dan Janney, managing director, Alta Partners; Mark McDade, CEO, Signature BioSciences, Inc.; Chris Ehrlich, senior associate, Interwest Partners

11:00 a.m. - 12:20 p.m.
Strategic Relationships and Minority Equity Investments: Corporate alliances and strategic relationships continue to proliferate in biotechnology as companies seek creative ways to develop and market new products and open new distribution channels. This panel will focus on the issues partners may face in structuring these transactions and how to resolve them.

Moderator: Michael W. Hall, partner, Latham & Watkins

Panelists: Charles Hoyng, partner, Latham & Watkins; Gayle Mills, vice president, business development, Abgenix, Inc.; Farah Champsi, managing director, Alta Partners; Jack Anthony, vice president, Business Development, FibroGen, Inc.; Joseph S. McCracken, DVM, vice president, business and commercial development, Genentech, Inc.; John O'Connor, director of licensing, Amgen

12:15p.m. - 2:20 pm
State Senator Deborah Ortiz (D-Sacramento)

Executive Focus on IT in Life Science Market
George Bloom, vice president 9i sales, North America, Oracle Corporation

2:00 - 3:20 pm
Positioning Your Intellectual Property Portfolio to Build Maximum Value: Panelists will discuss intellectual property issues, freedom-to-operate analyses, and how to build a global I.P. protection position. The panel will also outline what technology-oriented investors look for in a company's intellectual property.

Moderator: Bruce Jenett, co-chair, life sciences practice group, Heller Ehrman White & McAuliffe LLP

Panelists: Colin Sandercock, shareholder, Heller Ehrman White & McAuliffe LLP; Annika M. Reinemann, CFA, ASA, principal, Houlihan Valuation Advisors, Inc.; Christopher J. Woolley, senior vice president and managing director, technology and life sciences division, Comerica Bank; Edgar G. Engleman, MD, general partner, BioAsia Investments

3:30 - 5:00 pm
What Does the Venture Capital Community Look for in Early-Stage Drug Development Companies? Venture capitalists understand an investment in terms of value proposition, market potential and risks. Leading VCs will discuss the markets, strategies and commercialization options important to them, and how early-stage companies can frame their message for investors.

Moderator: Susan St. Sure, vice president, L.E.K. Consulting;

Panelists: Robert W. Overell, Ph.D., general partner, Frazier Healthcare Ventures; Brenda Gavin, managing partner, Quaker BioVentures; Chris Ehrlich, senior associates, Interwest Partners; Nicholas Simon, general partner, MPM Capital; James B. Tananbaum, MD, managing partner, Prospect Venture Partners; Deepa Pakianathan, Ph.D., partner, Delphi Ventures; Fred Middleton, general partner, Sanderling


BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit

# # #